A look at Denali Therapeutics Inc’s (DNLI) recent performance gives investors their first glimpse of hope.

On Friday, Denali Therapeutics Inc (NASDAQ: DNLI) was 4.08% up from the session before settling in for the closing price of $14.20. A 52-week range for DNLI has been $13.67 – $33.33.

During the last 5-year period, the sales growth of Healthcare Sector giant was 260.06%. When this article was written, the company’s average yearly earnings per share was at -12.77%. With a float of $125.71 million, this company’s outstanding shares have now reached $142.63 million.

Let’s determine the extent of company efficiency that accounts for 422 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Denali Therapeutics Inc (DNLI) Insider Activity

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Denali Therapeutics Inc stocks. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 88.03%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.

Denali Therapeutics Inc (DNLI) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -12.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.03% during the next five years compared to -4.46% drop over the previous five years of trading.

Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators

You can see what Denali Therapeutics Inc (DNLI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.46.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.58 in one year’s time.

Technical Analysis of Denali Therapeutics Inc (DNLI)

Looking closely at Denali Therapeutics Inc (NASDAQ: DNLI), its last 5-days average volume was 0.94 million, which is a drop from its year-to-date volume of 1.08 million. As of the previous 9 days, the stock’s Stochastic %D was 34.66%. Additionally, its Average True Range was 0.97.

During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 5.65%, which indicates a significant decrease from 42.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.29% in the past 14 days, which was lower than the 67.48% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $19.05, while its 200-day Moving Average is $23.23. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $15.07. Second resistance stands at $15.37. The third major resistance level sits at $15.89. If the price goes on to break the first support level at $14.25, it is likely to go to the next support level at $13.73. Should the price break the second support level, the third support level stands at $13.43.

Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats

There are 145,215K outstanding shares of the company, which has a market capitalization of 2.15 billion. As of now, sales total 0 K while income totals -422,770 K. Its latest quarter income was 0 K while its last quarter net income were -114,750 K.